The global Animal Health Cdmo Services Market is witnessing strong expansion as pharmaceutical companies increasingly outsource drug development and manufacturing for veterinary products. The market was valued at USD 7.1 billion in 2024 and is projected to reach USD 16.8 billion by 2033, expanding at a compound annual growth rate (CAGR) of 9.6% during the forecast period. Increasing livestock populations, rising pet ownership, and growing veterinary pharmaceutical spending are key factors driving this market.

Market Overview and Key Growth Metrics

The Animal Health Cdmo Services Market is gaining traction due to the rapid growth of veterinary biologics, vaccines, and pharmaceuticals. In 2023, the market generated approximately USD 6.5 billion, increasing to USD 7.1 billion in 2024, reflecting a year-over-year growth of 9.2%.

Industry forecasts suggest the market will reach USD 8.0 billion by 2025 and USD 11.7 billion by 2028, highlighting consistent outsourcing demand from global animal health companies. More than 65% of veterinary pharmaceutical firms now outsource at least part of their research, formulation, or manufacturing operations to specialized CDMO providers.

Historical Market Development (2016–2024)

Over the past decade, the Animal Health Cdmo Services Market has expanded steadily due to increasing global spending on animal healthcare.

In 2016, the market size stood at approximately USD 3.4 billion. By 2017, revenues rose to USD 3.8 billion, representing an annual growth of 11.8%.

The market continued expanding, reaching USD 4.3 billion in 2018 and USD 4.9 billion in 2019, driven by increased production of veterinary vaccines and parasiticides.

Despite pandemic disruptions, the market grew from USD 5.3 billion in 2020 to USD 5.8 billion in 2021. Continued growth pushed the market to USD 6.1 billion in 2022 and USD 6.5 billion in 2023, representing a five-year growth rate of nearly 52%.

Year-Over-Year Market Growth Trends

The Animal Health Cdmo Services Market has demonstrated consistent year-over-year growth as outsourcing strategies expand across the pharmaceutical industry.

Key year-over-year comparisons include:

• 2020–2021: Market increased from USD 5.3 billion to USD 5.8 billion, representing 9.4% growth.

• 2021–2022: Market rose to USD 6.1 billion, reflecting 5.1% growth.

• 2022–2023: Revenues reached USD 6.5 billion, showing 6.5% growth.

• 2023–2024: Market expanded to USD 7.1 billion, recording 9.2% growth.

This steady performance highlights the increasing reliance of pharmaceutical companies on contract manufacturing organizations to reduce production costs and accelerate product commercialization.

Regional Market Analysis

Geographically, the Animal Health Cdmo Services Market is dominated by North America and Europe due to strong pharmaceutical manufacturing capabilities.

North America accounted for approximately 41% of global revenue in 2024, equivalent to nearly USD 2.9 billion. The United States leads the region due to high veterinary healthcare spending exceeding USD 38 billion annually.

Europe represents the second-largest market with 31% share, valued at roughly USD 2.2 billion in 2024. Countries such as Germany, France, and the United Kingdom host major veterinary pharmaceutical manufacturers.

Asia-Pacific is the fastest-growing region, projected to expand at a CAGR of 11.3% through 2033. China and India collectively account for over 40% of global livestock populations, driving demand for outsourced veterinary drug production.

Latin America and Middle East & Africa together represent about 12% of the global market, supported by increasing investments in livestock disease management programs.

Service Segmentation and Market Demand

The Animal Health Cdmo Services Market is segmented into drug development, manufacturing, and packaging services.

Manufacturing services represent the largest segment, accounting for approximately 58% of total revenue in 2024. Pharmaceutical companies outsource manufacturing to reduce capital expenditure and regulatory burdens.

Drug development services contribute around 29% of the market, including formulation development, analytical testing, and clinical trial material production.

Packaging and supply chain services account for the remaining 13%, supporting global veterinary pharmaceutical distribution.

Biologics manufacturing is expected to grow fastest, with projected CAGR of 12.4% between 2025 and 2033, driven by increasing demand for animal vaccines and monoclonal antibody therapies.

Industry Investments and Corporate Activity

Significant investments are flowing into the Animal Health Cdmo Services Market as global demand for veterinary medicines increases.

Between 2020 and 2024, pharmaceutical companies invested more than USD 12 billion in expanding veterinary drug production facilities and CDMO partnerships.

Major animal health companies allocate approximately 8–12% of annual revenue to research and development, fueling outsourcing demand for specialized manufacturing capabilities.

The global veterinary pharmaceutical industry itself surpassed USD 46 billion in revenue in 2024, with CDMO services playing a critical role in supporting new product pipelines.

Additionally, government funding programs supporting livestock disease control collectively allocated over USD 5 billion globally between 2022 and 2025, boosting demand for vaccine manufacturing services.

Key Market Drivers and Industry Statistics

Several structural factors are accelerating the Animal Health Cdmo Services Market.

Global pet ownership rates increased by nearly 20% between 2018 and 2024, significantly expanding demand for veterinary medicines and biologics.

The global livestock population exceeded 36 billion animals in 2024, including cattle, poultry, and swine, creating strong demand for disease prevention and treatment products.

Veterinary biologics production volumes increased by approximately 11% annually since 2020, highlighting the growing importance of outsourced manufacturing capacity.

Industry surveys indicate that nearly 72% of veterinary pharmaceutical companies plan to increase outsourcing of drug development and manufacturing activities within the next five years.

Future Market Projections (2025–2033)

The Animal Health Cdmo Services Market is expected to maintain strong growth throughout the forecast period.

Market projections include:

• 2025: USD 8.0 billion

• 2027: USD 9.8 billion

• 2030: USD 13.5 billion

• 2033: USD 16.8 billion

This growth will be supported by increasing production of veterinary vaccines, rising demand for companion animal treatments, and expanding global livestock health programs.

By 2032, more than 60% of veterinary pharmaceutical production is expected to involve outsourced CDMO services, reflecting a major structural shift in the industry.

Conclusion: Data-Driven Outlook

The Animal Health Cdmo Services Market is becoming an essential component of the global veterinary pharmaceutical supply chain. With the market expanding from USD 6.5 billion in 2023 to USD 16.8 billion by 2033, the industry is expected to grow at a CAGR of 9.6%.

Rising pet healthcare spending, increasing livestock disease prevention initiatives, and expanding pharmaceutical outsourcing strategies are key growth drivers. Strong regional demand, particularly in North America and Asia-Pacific, combined with investments exceeding USD 12 billion, will continue fueling market expansion.

As veterinary drug pipelines grow and biologics manufacturing accelerates, the Animal Health Cdmo Services Market will remain a critical enabler of innovation and large-scale production in the global animal healthcare sector.

Read Full Research Study: https://marketintelo.com/report/animal-health-cdmo-services-market